EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Virchows Archiv

• Publication date

  2017-09-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00428-017-2226-8PMID 28884371
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.

  2017cited by this paper
• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

  2016cited by this paper
• ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

  2016cited by this paper
• Osimertinib as first‐line treatment for EGFR mutation‐positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts: LBA1_PR

  2016influential reference
• AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials.

  2016cited by this paper
• Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

  2016cited by this paper
• A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

  2016cited by this paper
• Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

  2015cited by this paper
• Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

  2015cited by this paper
• Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

  2015cited by this paper
• The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• EGFR mutations in lung cancer: from tissue testing to liquid biopsy.

  2015cited by this paper
• Pharmacotherapy targeting the EGFR oncogene in NSCLC

  2014cited by this paper
• Molecular Diagnostic Testing in Non-Small Cell Lung Cancer

  2014cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics

  2014cited by this paper
• Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

  2014cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013cited by this paper
• Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies

  2013cited by this paper
• Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients.

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013influential reference
• Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada.

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence.

  2013influential reference
• Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

  2013cited by this paper
• EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

  2012influential reference
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011influential reference
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

  2009cited by this paper
• F1000 highlights

  2009influential reference
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Circulating nucleic acids in plasma/serum

  2007cited by this paper
• Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

  2006cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper

• Trustworthy, self-fulfilling, non-redundant proficiency tests for metrological challenges in medical diagnostics

  2025cites this paper
• Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs

  2024cites this paper
• Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays

  2023cites this paper
• Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis

  2023cites this paper
• Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples.

  2022cites this paper
• Results of a worldwide external quality assessment of cfDNA testing in lung Cancer

  2022cites this paper
• Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue

  2022cites this paper
• The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer

  2022cites this paper
• Ringversuche – ein zentrales Mittel der externen Qualitätssicherung

  2022cites this paper
• Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer

  2021cites this paper
• The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

  2021cites this paper
• Pre-analytical issues in liquid biopsy – where do we stand?

  2020cites this paper
• Evolution of RAS testing over time: factors influencing mutation rates in metastatic colorectal cancer patients

  2020cites this paper
• External Quality Assessment schemes for biomarker testing in oncology: comparison of performance between formalin-fixed, paraffin-embedded-tissue and cell-free tumor DNA in plasma.

  2020cites this paper
• Predictive molecular pathology of lung cancer in Germany with focus on gene fusion testing: Methods and quality assurance

  2020cites this paper
• Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL

  2020cites this paper
• Diagnostik und Therapie des HER2-negativen metastasierten Mammakarzinoms 2020 Empfehlungen für die tägliche Routine (Sponsor: Roche Pharma AG)

  2020cites this paper
• A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories

  2019cites this paper
• Liquid Biopsy in der Tumordiagnostik

  2019cites this paper
• Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study

  2019cites this paper
• Liquid Biopsy and Genomic Assessment for Lung Cancer

  2019cites this paper
• The Translational Status of Cancer Liquid Biopsies

  2019cites this paper
• Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group

  2019cites this paper
• The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer

  2019cites this paper
• Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition.

  2019cites this paper
• Liquid Biopsy in der Tumordiagnostik

  2019cites this paper
• Liquid Biopsy in der Tumordiagnostik . Anwendungen , Perspektiven und Limitationen des Cancer Liquidome

  2019cites this paper
• A Comparative Study for Detection of EGFR Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories

  2018cites this paper
• Concordance of changes in the extracellular DNA of blood plasma and DNA of tumor tissue using the example of EGFR gene mutations in patients with non-small cell lung cancer

  2018cites this paper
• Experiencia argentina del uso compasivo de osimertinib

  2018cites this paper
• A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications

  2018influential citation